Exogenous Insulin Antibody Syndrome (EIAS) Presenting in an Elderly, Long-Term Patient with Type 1 Diabetes Mellitus that Resolved with Low-Cost Outpatient Therapy with Mycophenolate Mofetil and Regular Insulin by Pump
AbstractExogenous insulin antibody syndrome (EIAS) has until recently been a rarely described complication of exogenous insulin therapy. EIAS results not only in hyperglycemia, but also in hypoglycemia and occasionally in ketoacidosis (DKA). The incidence of EIAS is increasing probably due to an overall increase in autoimmunity associated with the coronavirus disease 2019 (Covid-19) epidemic resulting in increasing binding of insulin by antibodies. Herein, we describe a case of EIAS occurring in an elderly patient with longstanding type 1 diabetes mellitus (T1DM) who had progressive loss of glycemic control. It responded p...
Source: Diabetes Therapy - April 24, 2024 Category: Endocrinology Source Type: research
The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial —Study Design and Protocol
AbstractIntroductionMultiple daily injection insulin regimen (MDI) represents the most intensive insulin regimen used in the management of people with type 2 diabetes (PwT2D). Its efficacy regarding glycaemic control is counterbalanced by the increased risk of hypoglycaemia, frequently observed tendency to weight gain and necessity for frequent glucose monitoring. Recent introduction of novel antidiabetic medications with pleiotropic effects reaching far beyond the reduction of glycaemia (HbA1c), such as the glucagon-like peptide 1 receptor agonist (GLP-1 RA), has significantly widened the therapeutic options available for...
Source: Diabetes Therapy - April 24, 2024 Category: Endocrinology Source Type: research
Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study)
ConclusionsPhysicians should pay attention to side effects of SGLT2is to maintain the patients ’ QOL when SGLT2is are initiated or added-on. Add-on of luseogliflozin increased patients’ QOL more than DPP-4is. Considering patients’ QOL and treatment satisfaction is important for selecting SGLT2is or DPP-4is.Trial RegistrationUMIN000030128 and jRCTs031180241. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 24, 2024 Category: Endocrinology Source Type: research
Exogenous Insulin Antibody Syndrome (EIAS) Presenting in an Elderly, Long-Term Patient with Type 1 Diabetes Mellitus that Resolved with Low-Cost Outpatient Therapy with Mycophenolate Mofetil and Regular Insulin by Pump
AbstractExogenous insulin antibody syndrome (EIAS) has until recently been a rarely described complication of exogenous insulin therapy. EIAS results not only in hyperglycemia, but also in hypoglycemia and occasionally in ketoacidosis (DKA). The incidence of EIAS is increasing probably due to an overall increase in autoimmunity associated with the coronavirus disease 2019 (Covid-19) epidemic resulting in increasing binding of insulin by antibodies. Herein, we describe a case of EIAS occurring in an elderly patient with longstanding type 1 diabetes mellitus (T1DM) who had progressive loss of glycemic control. It responded p...
Source: Diabetes Therapy - April 24, 2024 Category: Endocrinology Source Type: research
The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial —Study Design and Protocol
AbstractIntroductionMultiple daily injection insulin regimen (MDI) represents the most intensive insulin regimen used in the management of people with type 2 diabetes (PwT2D). Its efficacy regarding glycaemic control is counterbalanced by the increased risk of hypoglycaemia, frequently observed tendency to weight gain and necessity for frequent glucose monitoring. Recent introduction of novel antidiabetic medications with pleiotropic effects reaching far beyond the reduction of glycaemia (HbA1c), such as the glucagon-like peptide 1 receptor agonist (GLP-1 RA), has significantly widened the therapeutic options available for...
Source: Diabetes Therapy - April 24, 2024 Category: Endocrinology Source Type: research
Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study)
ConclusionsPhysicians should pay attention to side effects of SGLT2is to maintain the patients ’ QOL when SGLT2is are initiated or added-on. Add-on of luseogliflozin increased patients’ QOL more than DPP-4is. Considering patients’ QOL and treatment satisfaction is important for selecting SGLT2is or DPP-4is.Trial RegistrationUMIN000030128 and jRCTs031180241. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 24, 2024 Category: Endocrinology Source Type: research
Correction to: Effect of Neo-Policaptil Gel Retard on Liver Fat Content and Fibrosis in Adults with Metabolic Syndrome and Type 2 Diabetes: A Non-invasive Approach to MAFLD
(Source: Diabetes Therapy)
Source: Diabetes Therapy - April 22, 2024 Category: Endocrinology Source Type: research
Real-World Effectiveness of the Gla-300 + Cap + App Program in Adult Users Living with Type 2 Diabetes in Taiwan
ConclusionsUse of digital technology within a connected ecosystem such as Gla-300 + Cap + App program could help people with type 2 diabetes to improve their glycemic condition. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 20, 2024 Category: Endocrinology Source Type: research
Basal Insulinotherapy in Patients Living with Diabetes in France: The EF-BI Study
ConclusionUse of Gla-300 resulted in a better persistence, less acute hospitalized events at least in T2DM, and reduced healthcare expenditure. These real-life results confirmed the potential interest of using Gla-300 rather than Gla-100. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 20, 2024 Category: Endocrinology Source Type: research
Psychosocial Self-efficacy and its Association with Selected Potential Factors Among Adults with Type 1 Diabetes: A Cross-Sectional Survey Study
ConclusionsIn this study, higher well-being score and lower self-reported HbA1c levels were associated with higher psychosocial self-efficacy in both univariate- and multivariate analysis and accounted for 30% of the variation in psychosocial self-efficacy in the regression model. Thus, measures to improve psychosocial self-efficacy in adults with type 1 diabetes may help maintain their psychological well-being and blood glucose control. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 20, 2024 Category: Endocrinology Source Type: research
Effects of Two COVID-19 Lockdowns on HbA1c Levels in Patients with Type 1 Diabetes and Associations with Digital Treatment, Health Literacy, and Diabetes Self-Management: A Multicenter, Observational Cohort Study Over 3 Years
ConclusionsLockdowns can lead to worsening glycemic control in patients with type 1 diabetes. Particularly patients with few check-ups, poor blood glucose values, deficits in diabetes self-management, low health literacy, and a low level of education seem to be at greater risk of worsening glycemic control during lockdowns and, therefore, require special medical care, e.g., through telemedicine.Trial RegistrationClinicalTrials.gov identifier, NCT04821921. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 20, 2024 Category: Endocrinology Source Type: research
Real-World Effectiveness of the Gla-300 + Cap + App Program in Adult Users Living with Type 2 Diabetes in Taiwan
ConclusionsUse of digital technology within a connected ecosystem such as Gla-300 + Cap + App program could help people with type 2 diabetes to improve their glycemic condition. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 20, 2024 Category: Endocrinology Source Type: research
Basal Insulinotherapy in Patients Living with Diabetes in France: The EF-BI Study
ConclusionUse of Gla-300 resulted in a better persistence, less acute hospitalized events at least in T2DM, and reduced healthcare expenditure. These real-life results confirmed the potential interest of using Gla-300 rather than Gla-100. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 20, 2024 Category: Endocrinology Source Type: research
Psychosocial Self-efficacy and its Association with Selected Potential Factors Among Adults with Type 1 Diabetes: A Cross-Sectional Survey Study
ConclusionsIn this study, higher well-being score and lower self-reported HbA1c levels were associated with higher psychosocial self-efficacy in both univariate- and multivariate analysis and accounted for 30% of the variation in psychosocial self-efficacy in the regression model. Thus, measures to improve psychosocial self-efficacy in adults with type 1 diabetes may help maintain their psychological well-being and blood glucose control. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 20, 2024 Category: Endocrinology Source Type: research
